Coya Therapeutics Inc (COYA) Stock Price, Quote & News

Company Profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 587 8170

Website: www.coyatherapeutics.com

Address:

5850 San Felipe St., Suite 500, Houston, United States

neuroinvestor3 Aug. 18 at 7:24 PM

$COYA $XBI $BMY

0 · Reply

Jwa68 Aug. 18 at 6:35 PM

$COYA $GANX The two most derisked and best asymmetric opportunities I have found in small biotech in the last 20 plus years. I suspect they both may look very different by year end.

0 · Reply

Jwa68 Aug. 18 at 3:46 PM

$COYA If i had cash, I would be adding.

0 · Reply

Robby83 Aug. 18 at 3:07 PM

$COYA flashing strength against the broader market correction. Take any pull back as a gift.

0 · Reply

RespectedElder Aug. 18 at 12:27 AM

$COYA great write up of our clinical study and its potential as a break through therapy for ALS.. In German, but this can be translated easily. Came out today: https://www.medicalblogs.de/als-therapie-durchbruch/

0 · Reply

foreverboner Aug. 15 at 3:28 AM

$COYA hopefully Coya can soon expand inclusion criteria to help ppl like Gregory

0 · Reply

zampy Aug. 15 at 1:21 AM

$COYA Very nice exposure Russo and company doing a nice job..Word will get out far more Sept 23rd to October 7thwhen we reach full enrollment imo.

0 · Reply

microcapspeculator Aug. 14 at 7:29 PM

$COYA A lot of positive press for Coya-302. Experimental ALS treatment being tested in Philadelphia: "There's potential here for a home run" By Stephanie Stahl, Will Kenworthy Updated on: August 13, 2026 / 6:43 PM EDT / CBS Philadelphia An experimental treatment being tested in Philadelphia could offer new hope for people with ALS. The current treatments for people with ALS are limited. The research on this new therapy is focused on the immune system, a new way to slow the progression of the disease. https://www.cbsnews.com/philadelphia/news/coya-treatment-als-temple/

0 · Reply

Jwa68 Aug. 14 at 7:16 PM

$ABCL $GANX $COYA Aging well and still miles to run. These 3 companies are going to impact a lot of patients and investors lives for the better.

1 · Reply

RespectedElder Aug. 14 at 3:42 PM

$COYA got a few more. Who is buying here? Just me and a handful of fellow investors?

1 · Reply

Coya Therapeutics reports Q2 EPS (28c), consensus (36c)

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Coya Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Coya Therapeutics Earnings release: Q2 2026

Aug 7, 2026, 7:00 AM EDT - 12 days ago

Coya Therapeutics Slides: Investor presentation

Jun 29, 2026, 7:00 AM EDT - 7 weeks ago

Coya Therapeutics Slides: Investor presentation

Jun 25, 2026, 1:00 PM EDT - 7 weeks ago

Coya Therapeutics Transcript: AGM 2026

Jun 24, 2026, 4:00 PM EDT - 7 weeks ago

Coya Therapeutics Transcript: Investor update

Jun 18, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease

2026-06-08T12:27:28.000Z - 2 months ago

Coya Therapeutics initiates first cohort of patients in ALSTARS trial

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase

2026-06-05T08:20:06.000Z - 2 months ago

Coya Therapeutics initiated with a Buy at Roth Capital

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Coya Therapeutics Slides: Investor presentation

May 27, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit

May 13, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Proxy statement: Proxy filing

May 13, 2026, 8:00 AM EDT - 3 months ago

Coya Therapeutics Proxy statement: Proxy filing

2026-05-12T11:54:30.000Z - 3 months ago

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

2026-05-12T11:49:47.000Z - 3 months ago

Coya Therapeutics reports Q1 EPS (32c), consensus (39c)

May 12, 2026, 7:35 AM EDT - 3 months ago

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 12, 2026, 7:30 AM EDT - 3 months ago

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

May 12, 2026, 7:30 AM EDT - 3 months ago

Coya Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 3 months ago

Coya Therapeutics Quarterly report: Q1 2026

May 11, 2026, 2:00 AM EDT - 3 months ago

Coya Therapeutics Slides: Investor presentation

May 1, 2026, 7:00 AM EDT - 3 months ago

Coya Therapeutics Slides: Corporate presentation

2026-04-09T12:26:37.000Z - 4 months ago

Coya Therapeutics announces publication of research on COYA 302

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

2026-04-02T12:17:50.000Z - 4 months ago

Coya Therapeutics Executive Chairman Howard Berman steps down

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Coya Therapeutics Slides: Investor presentation

2026-03-18T12:38:33.000Z - 5 months ago

Coya publishes study showing reduction in regulatory T cell function in FTD

Mar 18, 2026, 8:00 AM EDT - 5 months ago

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Coya Therapeutics Annual report: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Coya Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Coya Therapeutics Registration statement: Registration Filing

Feb 17, 2026, 3:00 PM EST - 6 months ago

Coya Therapeutics Transcript: Status update

Feb 17, 2026, 3:00 PM EST - 6 months ago

Coya Therapeutics Slides: Status update

Feb 10, 2026, 8:00 AM EST - 6 months ago

Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

2026-01-30T13:15:29.000Z - 7 months ago

Coya Therapeutics to sell 2.522M shares at $4.40 in private placement

RDY

Jan 30, 2026, 8:00 AM EST - 7 months ago

Coya Therapeutics Announces $11.1 Million Private Placement

Jan 20, 2026, 8:00 AM EST - 7 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Jan 8, 2026, 8:00 AM EST - 7 months ago

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

2026-01-05T13:05:21.000Z - 8 months ago

Coya Therapeutics announces FDA acceptance of COYA 302 IND application

Jan 5, 2026, 8:00 AM EST - 8 months ago

Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

2025-12-23T13:11:52.000Z - 8 months ago

Coya announces Health Canada acceptance of COYA 302 clinical trial application

Dec 23, 2025, 8:00 AM EST - 8 months ago

Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

2025-12-09T13:11:58.000Z - 9 months ago

Coya Therapeutics commences dosing in ALSTARS trial

Dec 9, 2025, 8:00 AM EST - 9 months ago

Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

Dec 2, 2025, 8:45 AM EST - 9 months ago

Coya Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 30, 2025, 6:00 PM EST - 9 months ago

Coya Therapeutics Slides: Investor Presentation

Nov 25, 2025, 8:00 AM EST - 9 months ago

Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

2025-11-12T13:20:43.000Z - 10 months ago

Coya Therapeutics reports Q3 EPS (13c), consensus (30c)

Nov 12, 2025, 8:00 AM EST - 10 months ago

Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Nov 12, 2025, 8:00 AM EST - 10 months ago

Coya Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Coya Therapeutics Earnings release: Q3 2025

2025-11-05T13:50:45.000Z - 10 months ago

Coya Therapeutics price target raised to $17 from $16 at Lake Street

2025-11-04T14:06:05.000Z - 10 months ago

Coya Therapeutics announces results from COYA 303 in vivo animal study

Nov 4, 2025, 8:00 AM EST - 10 months ago

Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

Oct 27, 2025, 4:01 PM EDT - 10 months ago

Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares

2025-10-24T10:35:20.000Z - 10 months ago

Coya Therapeutics 3.64M Spot Secondary priced at $5.50

Oct 24, 2025, 6:30 AM EDT - 10 months ago

Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

2025-10-23T20:35:37.000Z - 10 months ago

Coya Therapeutics announces common stock offering, no amount given

Oct 23, 2025, 4:31 PM EDT - 10 months ago

Coya Therapeutics Announces Proposed Public Offering of Common Stock

Oct 7, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

2025-09-29T12:10:10.000Z - 11 months ago

Coya Therapeutics completes enrollment in IL-2 and CTLA4-Ig study

Sep 29, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Sep 22, 2025, 8:00 AM EDT - 11 months ago

Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

Sep 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model

Sep 10, 2025, 10:00 AM EDT - 1 year ago

Coya Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial

Sep 3, 2025, 11:50 AM EDT - 1 year ago

PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies

Sep 3, 2025, 8:34 AM EDT - 1 year ago

Coya Therapeutics to Participate at Upcoming September Investor Conferences

Aug 25, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Registration statement: Registration Filing

Jul 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson's Disease

Jul 22, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

Jun 24, 2025, 10:30 AM EDT - 1 year ago

Coya Therapeutics Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2025

Jun 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

May 20, 2025, 12:30 PM EDT - 1 year ago

Coya Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 16, 2025, 10:53 AM EDT - 1 year ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Proxy statement: Proxy Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 8, 2025, 5:00 AM EDT - 1 year ago

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

REPL

Apr 24, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Apr 23, 2025, 2:00 PM EDT - 1 year ago

Coya Therapeutics Transcript: Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 9:51 AM EDT - 1 year ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Apr 1, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

Mar 26, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Mar 18, 2025, 8:15 AM EDT - 1 year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Coya Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

Feb 11, 2025, 10:00 AM EST - 1 year ago

Coya Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Feb 4, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 21, 2025, 8:15 AM EST - 1 year ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

neuroinvestor3 Aug. 18 at 7:24 PM

$COYA $XBI $BMY

0 · Reply

Jwa68 Aug. 18 at 6:35 PM

$COYA $GANX The two most derisked and best asymmetric opportunities I have found in small biotech in the last 20 plus years. I suspect they both may look very different by year end.

0 · Reply

Jwa68 Aug. 18 at 3:46 PM

$COYA If i had cash, I would be adding.

0 · Reply

Robby83 Aug. 18 at 3:07 PM

$COYA flashing strength against the broader market correction. Take any pull back as a gift.

0 · Reply

RespectedElder Aug. 18 at 12:27 AM

0 · Reply

foreverboner Aug. 15 at 3:28 AM

$COYA hopefully Coya can soon expand inclusion criteria to help ppl like Gregory

0 · Reply

zampy Aug. 15 at 1:21 AM

$COYA Very nice exposure Russo and company doing a nice job..Word will get out far more Sept 23rd to October 7thwhen we reach full enrollment imo.

0 · Reply

microcapspeculator Aug. 14 at 7:29 PM

0 · Reply

Jwa68 Aug. 14 at 7:16 PM

$ABCL $GANX $COYA Aging well and still miles to run. These 3 companies are going to impact a lot of patients and investors lives for the better.

1 · Reply

RespectedElder Aug. 14 at 3:42 PM

$COYA got a few more. Who is buying here? Just me and a handful of fellow investors?

1 · Reply

zampy Aug. 14 at 1:03 PM

$COYA On the CBS Philly broadcast last night the metaphor used by Dr Heiman Patterson could be a " HOMERUN" is very atypical comment for an ALS expert..Normally they day it shows promise.. BIG TELL.....1st time ever Dr Heiman Patterson used that word home run on a broadcast....

1 · Reply

Jwa68 Aug. 14 at 12:27 PM

$COYA If i had extra free cash, I'd be adding to my already large position that i added to last week. This opportunity will likely soon be extinguished at these levels. On fact, it may be extinguished forever with a new name on the door.

1 · Reply

Jwa68 Aug. 13 at 11:28 PM

$COYA Hard to keep a good secret...$XBI $BMY https://www.cbsnews.com/philadelphia/video/promising-research-for-als-treatment-underway-at-temple-health-in-philadelphia/

1 · Reply

zampy Aug. 13 at 8:46 PM

$COYA So over the last 4 months I did the Due diligence $COYA's VWAP has been higher thsn the close 70% of the time. I dont believe in coincidences....Draw your own conclusions.

2 · Reply

zampy Aug. 13 at 8:36 PM

$COYA Yesterday close $4.69 VWAP $4.75...Today close $4.67 VWAP $4.75 SKUNK IN WOOD PILE LAST 40 MINUTES..I have seen this often with COYA. I have my thoughts but will refrain.

1 · Reply

microcapspeculator Aug. 13 at 3:51 PM

$COYA Nice to see why a leading expert says this trial is different for ALS.

0 · Reply

Robby83 Aug. 13 at 3:26 PM

$COYA strong resistance at $4.80-4.85

0 · Reply

BG_BULL Aug. 12 at 10:24 AM

$COYA He failed to mention that Phase 2 will very likely be sufficient to seek approval, and there will be no need to go through Phase 3.

0 · Reply

Jwa68 Aug. 11 at 5:39 PM

$COYA Nice shout out in this interview... https://www.youtube.com/watch?v=0Ck7SR_4mhk&t=3s

2 · Reply

wsrjeff Aug. 11 at 2:22 PM

$COYA There is a new audio Interview of Dr. Arun Swaminathan Ph.D., CEO of Coya Therapeutics. Inc. (COYA) @CoyaTx A clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders. Listen at The Wall Street Resource https://thewallstreetresource.com/webcasts/

3 · Reply

Jwa68 Aug. 11 at 1:26 PM

$COYA Nice interview. https://thewallstreetresource.com/webcasts/

0 · Reply

focafoca99 Aug. 11 at 12:12 PM

$COYA shared its June-30, 2026 quarter results in a press release.

0 · Reply

Market Cap	109.55M
Revenue (ttm)	7.95M
Net Income (ttm)	-21.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-267.04%
Debt to Equity Ratio	0.00

Volume	106,600
Avg Vol	206,026
Day's Range	N/A - N/A
Shares Out	23.46M
Stochastic %K	98%
Beta	0.61
Analysts	Strong Sell
Price Target	$15.19